4 February 2021 - Newsletter

Salvia receives Breakthrough Device Designation from American FDA

The Dutch medtech company Salvia BioElectronics B.V. specialises in the treatment of chronic migraine with electromedical solutions for neurostimulation. The news that Salvia has received the coveted Breakthrough Device Designation from the United States FDA gives creates a reason for hope among millions of migraine patients in the USA. This will significantly accelerate the approval process for the US market.

Read more about it here: https://t1p.de/0od6